Grant of Interim Extension of the Term of U.S. Patent No. 4,591,585; atamestane, 34896-34897 [E6-9489]

Download as PDF 34896 Federal Register / Vol. 71, No. 116 / Friday, June 16, 2006 / Notices Partial Rescission of Review On June 1, 2006, CES timely withdrew its request for an administrative review of its sales during the above–referenced period. Section 351.213(d)(1) of the Department’s regulations requires that the Secretary rescind an administrative review if a party requesting a review withdraws the request within 90 days of the date of publication of the notice of initiation. In this case, CES has withdrawn its request for review within the 90-day period. We have received no other submissions regarding CES’s withdrawal of its request for review. Therefore, we are rescinding in part this review of the antidumping duty order on stainless steel bar from the United Kingdom with respect to CES. This review will continue with respect to Firth Rixson. This notice is published in accordance with section 751 of the Tariff Act of 1930, as amended, and 19 CFR 351.213(d)(4). Dated: June 12, 2006. Stephen J. Claeys, Deputy Assistant Secretary for Import Administration. [FR Doc. E6–9474 Filed 6–15–06; 8:45 am] Kate Swails or Shane Guan (301)713–2289. FOR FURTHER INFORMATION CONTACT: BILLING CODE 3510–DS–S National Oceanic and Atmospheric Administration [I.D. 060706D] Endangered Species; File No. 1578 National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce. ACTION: Notice; Receipt of application. wwhite on PROD1PC61 with NOTICES AGENCY: SUMMARY: Notice is hereby given that the Maine Department of Marine Resources (MDMR) (Gail S. Wippelhauser, Principal Investigator), 21 State House Station, Augusta, ME 04333 has applied in due form for a permit to take shortnose sturgeon (Acipenser brevirostrum) for purposes of scientific research. DATES: Written, telefaxed, or e-mail comments must be received on or before July 17, 2006. ADDRESSES: The application and related documents are available for review upon written request or by appointment in the following office(s): Permits, Conservation and Education Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910; phone (301)713–2289; fax (301)427–2521; and 18:25 Jun 15, 2006 The subject permit is requested under the authority of the Endangered Species Act of 1973, as amended (ESA; 16 U.S.C. 1531 et seq.) and the regulations governing the taking, importing, and exporting of endangered and threatened species (50 CFR 222–226). The applicant proposes to determine the location of spawning and feeding habitat, and migratory pathways of sturgeon in the Penobscot and Kennebec Rivers in Maine. The study would also determine the impact of river flows on migration and habitat use. Researchers would annually capture up to 250 sturgeon from the Penobscot River during the study’s first three years. Up to 500 sturgeon would be captured annually from the Kennebec River during the last two years of the study. Sturgeon would be captured with gillnets, measured, weighed, tissue sampled, Passive Integrated Transponder tagged, and released. A sample of sturgeon would be acoustic tagged. Researchers would also sample for eggs and larvae. The permit would be issued for five-years. SUPPLEMENTARY INFORMATION: DEPARTMENT OF COMMERCE VerDate Aug<31>2005 Northeast Region, NMFS, One Blackburn Drive, Gloucester, MA 019302298; phone (978)281–9328; fax (978)281–9394. Written comments or requests for a public hearing on this application should be mailed to the Chief, Permits, Conservation and Education Division, F/PR1, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910. Those individuals requesting a hearing should set forth the specific reasons why a hearing on this particular request would be appropriate. Comments may also be submitted by facsimile at (301)427–2521, provided the facsimile is confirmed by hard copy submitted by mail and postmarked no later than the closing date of the comment period. Comments may also be submitted by email. The mailbox address for providing email comments is NMFS.Pr1Comments@noaa.gov. Include in the subject line of the email comment the following document identifier: File No. 1578. Jkt 208001 Dated: June 12, 2006. P. Michael Payne, Chief, Permits, Conservation and Education Division, Office of Protected Resources, National Marine Fisheries Service. [FR Doc. E6–9501 Filed 6–15–06; 8:45 am] BILLING CODE 3510–22–S PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. PTO–P–2006–0032] Grant of Interim Extension of the Term of U.S. Patent No. 4,591,585; atamestane United States Patent and Trademark Office, Commerce. ACTION: Notice of Interim Patent Term Extension. AGENCY: SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a third one-year interim extension of the term of U.S. Patent No. 4,591,585. FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 272– 7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450, Alexandria, VA 22313–1450; by fax marked to her attention at (571) 273– 7755, or by e-mail to Mary.Till@uspto.gov. Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On May 9, 2006, Intarcia Therapeutics, Inc., exclusive licensee of U.S. Patent No. 4,591,585, assigned to Schering Aktiengesellschaft, timely filed an application under 35 U.S.C. 156(d)(5) for a third interim extension of the term of U.S. Patent No. 4,591,585. The patent claims the human drug product atamestane. The application indicates that a New Drug Application for the human drug product atamestane has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (June 18, 2006), interim extension of the SUPPLEMENTARY INFORMATION: E:\FR\FM\16JNN1.SGM 16JNN1 Federal Register / Vol. 71, No. 116 / Friday, June 16, 2006 / Notices patent term under 35 U.S.C. 156(d)(5) is appropriate. A third interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,591,585 is granted for a period of one year from the expiration date of the patent, i.e., until June 18, 2007. Dated: June 12, 2006. Jon W. Dudas Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. [FR Doc. E6–9489 Filed 6–15–06; 8:45 am] BILLING CODE 3510–16–P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. PTO–P–2006–0033] Grant of Interim Extension of the Term of U.S. Patent No. 4,585,597; ´ ANTHELIOS SP (HELIOBLOCK SX Cream) (Mexoryl SX (Ecamsule)) United States Patent and Trademark Office, Commerce. ACTION: Notice of Interim Patent Term Extension. AGENCY: SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a fourth one-year interim extension of the term of U.S. Patent No. 4,585,597. FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 272– 7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450, Alexandria, VA 22313–1450; by fax marked to her attention at (571) 273– 7755, or by e-mail to Mary.Till@uspto.gov. Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On May 16, 2006, patent owner, L Oreal S.A., timely filed an application under 35 U.S.C. 156(d)(5) for a fourth subsequent interim extension of the term of U.S. Patent No. 4,585,597. The patent claims the active ingredient Mexoryl SX (ecamsule), in the human drug product ANTHELIOS SP (HELIOBLOCK SX Cream), a method of wwhite on PROD1PC61 with NOTICES SUPPLEMENTARY INFORMATION: VerDate Aug<31>2005 18:25 Jun 15, 2006 Jkt 208001 use of the active ingredient, and a method of manufacturing the active ingredient. The application indicates, and the Food and Drug Administration has confirmed, that a New Drug Application for the human drug product Mexoryl SX (ecamsule) has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. Review of the application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for an additional year as required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (June 16, 2006), interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. A fourth interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,585,597 is granted for a period of one year from the extended expiration date of the patent, i.e., until June 16, 2007. Dated: June 12, 2006. Jon W. Dudas, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. [FR Doc. E6–9490 Filed 6–15–06; 8:45 am] BILLING CODE 3510–16–P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. PTO–P–2006–0019] Grant of Interim Extension of the Term of U.S. Patent No. 4,850,962; Esteem (Totally Implantable Hearing System) United States Patent and Trademark Office, Commerce. ACTION: Notice of Interim Patent Term Extension. AGENCY: SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 4,850,962. FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 272– 7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450, Alexandria, VA 22313–1450; by fax marked to her attention at (571) 273– 7755, or by e-mail to Mary.Till@uspto.gov. PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 34897 Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On March 31, 2006, patent owner, Envoy Medical Corporation, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 4,850,962. The patent claims the medical device Esteem (totally implantable hearing system). The application indicates that an Investigational Device Exemption for the medical device Esteem has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the original expiration date of the patent (July 25, 2006), interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,850,962 is granted for a period of one year from the original expiration date of the patent, i.e., until July 25, 2007. SUPPLEMENTARY INFORMATION: Dated: June 12, 2006. Jon W. Dudas, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. [FR Doc. E6–9494 Filed 6–15–06; 8:45 am] BILLING CODE 3510–16–P COMMODITY FUTURES TRADING COMMISSION Sunshine Act Meeting TIME AND DATE: 11 a.m., Friday, July 7, 2006. 1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room. STATUS: Closed. MATTERS TO BE CONSIDERED: Surveillance Matters. PLACE: E:\FR\FM\16JNN1.SGM 16JNN1

Agencies

[Federal Register Volume 71, Number 116 (Friday, June 16, 2006)]
[Notices]
[Pages 34896-34897]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-9489]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

 Patent and Trademark Office

[Docket No. PTO-P-2006-0032]


Grant of Interim Extension of the Term of U.S. Patent No. 
4,591,585; atamestane

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of Interim Patent Term Extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued a 
certificate under 35 U.S.C. 156(d)(5) for a third one-year interim 
extension of the term of U.S. Patent No. 4,591,585.

FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 
272-7755; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450, 
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755, or by e-mail to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to a year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On May 9, 2006, Intarcia Therapeutics, Inc., exclusive licensee of 
U.S. Patent No. 4,591,585, assigned to Schering Aktiengesellschaft, 
timely filed an application under 35 U.S.C. 156(d)(5) for a third 
interim extension of the term of U.S. Patent No. 4,591,585. The patent 
claims the human drug product atamestane. The application indicates 
that a New Drug Application for the human drug product atamestane has 
been filed and is currently undergoing regulatory review before the 
Food and Drug Administration for permission to market or use the 
product commercially.
    Review of the application indicates that except for permission to 
market or use the product commercially, the subject patent would be 
eligible for an extension of the patent term under 35 U.S.C. 156, and 
that the patent should be extended for one year as required by 35 
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review 
period will continue beyond the extended expiration date of the patent 
(June 18, 2006), interim extension of the

[[Page 34897]]

patent term under 35 U.S.C. 156(d)(5) is appropriate.
    A third interim extension under 35 U.S.C. 156(d)(5) of the term of 
U.S. Patent No. 4,591,585 is granted for a period of one year from the 
expiration date of the patent, i.e., until June 18, 2007.

    Dated: June 12, 2006.
Jon W. Dudas
Under Secretary of Commerce for Intellectual Property and Director of 
the United States Patent and Trademark Office.
[FR Doc. E6-9489 Filed 6-15-06; 8:45 am]
BILLING CODE 3510-16-P